
News|Articles|December 1, 2005
FDA actions in brief
The injectable antibiotic ertapenem (Invanz, Merck) was approved by FDA to treat moderate-to-severe complicated foot infections due to indicated pathogens in patients who have diabetes without osteomyelitis
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Positive results for Casgevy but with one patient death from myeloablative busulfan conditioning | ASH 2025
2
IV iron treatment improves survival, increases hemoglobin levels in anemic patients with acute bacterial infection | ASH 2025
3
Quadruplet treatments for multiple myeloma are rising but access varies | ASH 2025
4
AstraZeneca’s Imfinzi gains landmark FDA approval for early gastric and gastroesophageal cancers
5






















































